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ABSTRACT 
BACKGROUND: Anemia is a predictor of adverse outcomes in acute myocardial infarction. We studied 
the relationship of hemoglobin, or its change over time, and outcomes in patients with stable coronary 
artery disease. 
METHODS: CLARIFY is a prospective, cohort study of outpatients with stable coronary artery disease 
(32,901 in 45 countries 2009-2010); 21,829 with baseline hemoglobin levels. They were divided into 
hemoglobin quintiles and anemia status (anemic [A] or normal [N]) at baseline/follow-up: N/N; A/N; N/A; 
A/A. All-cause mortality, cardiovascular events, and major bleeding at 4-year follow-up were assessed. 
RESULTS: Low baseline hemoglobin was an independent predictor of all-cause, cardiovascular, and 
noncardiovascular mortality, the composite of cardiovascular death/myocardial infarction or stroke and 
major bleeds (all P <.001; unadjusted models). Anemia at follow-up was independently associated with 
all-cause mortality (hazard ratio [HR], 1.90; 95% confidence interval [CI], 1.55-2.33 for A/A; 1.87; 1.54-
2.28 for N/A; both P <.001), noncardiovascular mortality (P <.001), and cardiovascular mortality (P = 
.001). Patients whose baseline anemia normalized (A/N) were not at increased risk of death (HR, 1.02; 
95% CI, 0.77-1.35), although risk of major bleeding was greater (HR, 2.06; 95% CI, 1.23-3.44; P = .013) 
than in those with normal hemoglobin throughout. Sensitivity analyses excluding patients with heart 
failure and chronic kidney disease at baseline yielded qualitatively similar results. 
CONCLUSION: In this large stable coronary artery disease population, low hemoglobin was an 
independent predictor of mortality, cardiovascular events, and major bleeds. Persisting or new-onset 
anemia is a powerful predictor of cardiovascular and noncardiovascular mortality. 
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INTRODUCTION 
Anemia is a risk factor for cardiovascular disease in the general population.1 Anemia is also an 
independent predictor of adverse outcomes in acute coronary syndromes.2-4 In addition, lower 
hemoglobin levels or anemia independently predict higher mortality after percutaneous coronary 
intervention5 or coronary artery bypass graft surgery.6  
 Anemia may be associated with elevated levels of inflammatory mediators,7 and inflammation is 
associated with atherosclerotic progression.8 As such, anemia could theoretically contribute to 
progression of coronary artery disease. However, coexisting conditions (cardiovascular and other) are 
also intricately related to both inflammation and hemoglobin levels and it remains uncertain as to whether 
anemia is causally implicated in adverse outcomes or whether it is a marker of other, or advanced, 
disease. For example, a particularly strong adverse relationship is seen between anemia and outcomes in 
heart failure.9,10  
 Little is known regarding the relationship of hemoglobin or change in anemia status over time and 
cardiovascular events and mortality in stable coronary artery disease. The aims of the current analysis 
from the large contemporary global CLARIFY (ProspeCtive observational LongitudinAl RegIstry oF 
patients with stable coronary arterY disease) registry were to assess the relationship between 
hemoglobin, or change in anemia status over time, and 4-year mortality and cardiovascular and major 
bleeding events. We hypothesized that both lower baseline hemoglobin and change in hemoglobin over 
time would be associated with mortality and adverse cardiovascular events. 
 
METHODS 
Ethics Statement 
The study was conducted in accordance with the principles in the Declaration of Helsinki. Local ethical 
approval was obtained as necessary in all countries prior to recruitment. All patients provided written 
informed consent.  
 
Study Design and Patients 
CLARIFY is an international, prospective, longitudinal cohort study involving outpatients with stable 
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coronary artery disease.11-14 The study was established to characterize outpatients with stable coronary 
artery disease in terms of clinical profiles, therapeutic strategies, and outcomes. Patients are followed up 
with annual visits for 5 years, with interim telephone calls every 6 months to maximize participant 
retention. Data collected included demographics, medical history, risk factors and lifestyle, physical 
condition and vital signs, current symptoms and treatments. Presence of diabetes or dyslipidemia reflects 
a history of these conditions. Patients were asked about their symptoms of heart failure; when present, 
symptoms were categorized per New York Heart Association class. Physical activity was graded 
according to the amount undertaken per week. Treatment is per usual local clinical practice. Laboratory 
and other test (invasive and noninvasive) results were collected, but no test was mandated by the study 
protocol.  
Patients were required to have stable coronary artery disease, defined as history of ≥1 of the 
following: previous (>3 months before enrolment) documented myocardial infarction or coronary 
revascularization procedure; coronary stenosis >50% at angiography; or chest pain with evidence of 
myocardial ischaemia (stress electrocardiogram, stress echocardiograph or myocardial perfusion 
imaging). Exclusion criteria included recent (≤3 months) hospitalization for a cardiovascular reason 
(including revascularization), planned revascularization, or conditions hampering participation for the 5-
year follow-up. Anemia was not an exclusion criterion.  
To ensure patients were representative of stable coronary artery disease outpatients, recruitment 
of sites was based on selection of physicians (n = 2884, including cardiologists, office-based primary care 
physicians, and physicians based in hospitals with outpatient clinics) by national coordinators, using the 
best available epidemiological data in each country reflecting the burden of coronary artery disease. To 
reduce selection bias, each participating physician was asked to recruit 10-15 consecutive stable 
outpatients with coronary artery disease over a short period to meet a predefined country target of 25 
patients per million inhabitants (range 12.5-50). 
This analysis focused on patients with available hemoglobin data at baseline (collection of these 
data was not mandated for study enrolment). Patients were grouped according to quintile of baseline 
hemoglobin to permit comparison of characteristics and treatments between the groups and the 
relationship with 4-year outcomes (quintile 1: <12.80 g/dL; quintile 2: 12.80-13.69 g/dL; quintile 3: 13.70-
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14.40 g/dL; quintile 4: 14.41-15.20 g/dL; and quintile 5: >15.20 g/dL). In this analysis, the primary 
endpoint was all-cause mortality at 4-year follow up, with secondary cardiovascular mortality and major 
bleeding endpoints. Major bleeding was defined as that requiring hospitalization or blood transfusion.  
Anemia was defined according to World Health Organization criteria as hemoglobin <13 g/dL for 
men and <12 g/dL for women.15 To evaluate change in anemia status over time with 4-year outcomes, 
patients were divided into four groups according to the presence or absence of anemia at baseline and at 
follow-up, respectively: Normal/Normal (N/N); Anemic/Normal (A/N); Normal/Anemic (N/A); and 
Anemic/Anemic (A/A). Analysis of the effect of the change in hemoglobin on the outcome used the latest 
available hemoglobin value prior to each event.  
 
Statistical Analysis 
All CLARIFY data are collected and analyzed at an independent academic statistics center (Robertson 
Centre for Biostatistics, University of Glasgow, UK) that is responsible for the management of the 
database, all analyses (using the SAS statistical program, version 9.2 or higher), and storing the data 
according to regulations. Baseline characteristics, according to hemoglobin quintiles, are presented using 
descriptive statistics with mean (standard deviation [SD]) or median (quartile 1, quartile 3 [Q1, Q3]) for 
continuous variables, depending on the distribution of the data, and as counts (percentages) for 
categorical data.  
 Comparisons between the hemoglobin quintiles were made using either one-way analysis of 
variance or the Kruskal-Wallis test for continuous data, depending on the distribution of the data, or the 
chi-square test for categorical data. 
 The primary and secondary endpoints were evaluated with the use of univariate and multivariable 
Cox proportional hazards models to examine the effect of the hemoglobin quintiles on each of the 
endpoints, with the multivariable model adjusting for clinical and demographic baseline variables known 
to have a relationship with these endpoints, and included the following: age, sex, geographic region, 
smoking status, systolic blood pressure, diastolic blood pressure, history of heart failure, dyslipidemia, 
history of myocardial infarction, history of percutaneous coronary intervention, history of coronary artery 
bypass graft, left ventricular ejection fraction, peripheral artery disease, asthma/chronic obstructive 
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pulmonary disease, diabetes mellitus and renal function, where renal function was calculated using the 
Chronic Kidney Disease-Epidemiological Collaboration (CKD-EPI) formula for estimated glomerular 
filtration rate.16 Similar Cox proportional hazards models were produced to examine the effect of the 
change in hemoglobin on each of the endpoints. These models included the above-noted four-level 
categorical variable, indicating the presence or absences of anemia in patients at baseline and at follow-
up visits, instead of the hemoglobin quintiles. 
 Sensitivity analyses were performed, excluding patients with heart failure, and separately patients 
with severe chronic kidney disease at baseline. Severe chronic kidney disease was defined as estimated 
glomerular filtration rate <30 mL/min/1.73 m2. 
 
RESULTS 
A total of 33,375 patients were enrolled in 45 countries between November 2009 and June 2010. Four 
hundred seventy-four patients were excluded as they did not meet the study criteria, did not provide 
informed consent, or were missing ethics committee approval (Figure 1). Of the remaining 32,901 
patients, baseline hemoglobin level was available in 21,829 patients and formed the study group. The 
mean age was 64 ± 10 years, 77.4% were male, and mean hemoglobin was 14.0 ± 1.5 g/dL. At baseline, 
11.0% of men and 13.1% of women were anemic.  
 Baseline characteristics of the study population according to hemoglobin quintile are shown in 
Table 1. The profiles of the quintiles differed. For example, age decreased steadily with increasing 
quintiles of hemoglobin; the percentage of men and the median body mass index increased from quintile 
1 to quintile 5, whilst the converse was seen for age. Patients in the higher quintiles were more likely to 
be smokers and consume alcohol but less likely to be sedentary. They also had a longer duration of 
coronary artery disease and were more likely to have had a myocardial infarction or undergone 
percutaneous coronary intervention but less likely to have had coronary artery bypass graft. Patients in 
the lower quintiles had higher rates of prior hospitalization for heart failure and had higher prevalences of 
coexisting conditions, most notably diabetes. The prevalence of left bundle branch block decreased from 
quintile 1 to quintile 5; the opposite was seen for the mean concentration of triglycerides and estimated 
glomerular filtration rate (Table 2). 
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 Whilst patients with lower hemoglobin were less commonly treated with aspirin and angiotensin-
converting enzyme inhibitors, they more commonly received thienopyridines, anticoagulants, angiotensin 
receptor blockers, calcium antagonists, proton pump inhibitors, antihypertensive medications, 
nonsteroidal anti-inflammatory, and antidiabetic drugs (Table 3). 
 
Outcomes According to Hemoglobin Status  
In univariate analysis (Figure 2A), all-cause mortality, cardiovascular mortality (quintile 1 only), 
noncardiovascular mortality, and major bleeding were significantly more common in the lowest two 
quintiles as compared with quintile 3. Following multivariable adjustment (Figure 2B), with quintile 3 as 
reference, patients in quintile 1 more commonly experienced all-cause and cardiovascular mortality and 
major bleeding whilst patients in quintile 2 more commonly experienced noncardiovascular mortality and 
major bleeding (trend for all-cause mortality). A composite of cardiovascular death, myocardial infarction, 
or stroke was more commonly seen in quintiles 1 and 2 (trend for quintile 5) as compared with quintile 3. 
As sex is a strong predictor of both mortality and hemoglobin level, separate analyses have been done for 
men and women (Appendix 2).  
 
Outcomes According to Change in Hemoglobin Status  
Additional hemoglobin data at follow-up were available for a subset of 17,584 subjects, most of whom 
were not anemic at baseline and at follow-up. In univariate (Figure 3A) and multivariable (Figure 3B) 
analysis, anemia status at follow-up (N/A or A/A) was associated with an increased risk of mortality (all-
cause, cardiovascular, and noncardiovascular) as compared to patients without anemia during the study 
(N/N). Patients whose baseline anemia normalized during follow-up (A/N) did not appear to be at 
increased risk of death, although risk of major bleeding was greater following multivariable analysis. The 
results were qualitatively similar when major bleeding outcomes were further adjusted for oral 
anticoagulant use at baseline.  
 Sensitivity analyses were performed after excluding patients with heart failure and severe chronic 
kidney disease at baseline and yielded qualitatively similar results.  
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DISCUSSION 
In this large international contemporary stable coronary artery disease population, low hemoglobin at 
baseline was an independent predictor of mortality, adverse cardiovascular events, and major bleeds 
when assessed over a 4-year period. Persisting or new onset anemia was an independent powerful 
predictor of cardiovascular and noncardiovascular mortality. In contrast, patients whose anemia 
normalized over time did not appear to have an excess mortality risk, although their risk of major bleeding 
was increased relative to patients without anemia. Whilst low hemoglobin levels may play a 
pathophysiological role in cardiovascular disease progression, and thereby adverse events, these data 
suggest that it may also be a marker of coexisting disease. 
 Published studies have focused on the relationship between anemia and outcomes in patients 
presenting with acute coronary syndromes3,4,17,18 and/or undergoing revascularization, with variable 
lengths of follow-up.5,19 Many of these were single center experiences.2,18,19 Anemia at baseline has 
consistently been shown to predict adverse outcome. For example, data from the Acute Catheterization 
and Urgent Intervention Triage StrategY (ACUITY) trial showed that anemia was an independent 
predictor of 1-year mortality and major bleeding at 1 month.4 A meta-analysis of 27 studies of patients 
with acute coronary syndromes (n = 233,144) found that anemia was associated with comorbidities and 
was an independent predictor of all-cause mortality.3 In contrast, few studies have evaluated patients with 
stable coronary artery disease. Muzarelli et al.20 evaluated data in 253 elderly subjects (≥75 years) with 
symptomatic stable coronary artery disease from the TIME study and found that anemia was an 
independent predictor of all-cause and cardiovascular mortality. Anemia was a predictor of a composite of 
cardiovascular events when evaluated in 143 subjects undergoing first diagnostic angiogram for stable 
angina and proven coronary artery disease (>50% luminal narrowing).21 
 The current study contributes to our understanding of the relationship of hemoglobin and change 
in anemia status in stable coronary artery disease, having recruited a large (21,829 patients) and 
representative (multicenter from 45 countries) population with long-term follow-up (4 years). 
 A relationship between heart failure and low hemoglobin is well established22; presence of 
anemia is a powerful predictor of adverse outcomes in heart failure. Relatively few patients in the 
CLARIFY study had a history of heart failure at baseline (83.2% had no symptoms of heart failure) and 
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mean left ventricular ejection fraction was 56% (noting that data on left ventricular function were not 
systematically required for the study). To ensure that this group was not driving the main results of the 
study, sensitivity analysis, following the exclusion of patients with symptoms of heart failure, were 
performed and revealed qualitatively similar results. There is an intricate relationship between advanced 
chronic kidney disease and hemoglobin, and chronic kidney disease is an independent predictor of 
adverse outcomes for patients presenting with many different cardiovascular disorders. As such, the 
sensitivity analyses excluding patients with severe chronic kidney disease (estimated glomerular filtration 
rate <30 mL/min/1.73 m2) add weight to establishing low hemoglobin as an independent predictor of 
events in patients with stable coronary artery disease. 
 Few studies have evaluated the effect of change in hemoglobin or anemia status over time in 
patients with coronary artery disease. A retrospective analysis of patients surviving to at least 6 months 
following a myocardial infarction showed that the last hemoglobin measurement had the highest 
prognostic power and that hemoglobin decrement was associated with an increased risk of all-cause 
mortality and recurrent cardiovascular events even among nonanemic patients at baseline.23 Ang et al.2 
evaluated 448 patients presenting with acute coronary syndrome with hemoglobin assessment at 
baseline and 7 weeks. They found a doubling of the prevalence of anemia by 7 weeks and that its 
presence at either time point was an independent predictor of adverse prognosis. Our current study 
evaluated data from a subset of 17,584 patients and highlights that anemia at follow-up is an important 
independent predictor of all-cause, cardiovascular, and noncardiovascular mortality in stable coronary 
artery disease. When anemia normalizes over time, this relationship is lost. Anemia at baseline is a 
correlate of major bleeds; this is unlikely to be a causative relationship and more likely identifies patients 
at higher bleeding risk, perhaps reflecting prior blood loss. 
 Patient characteristics differed according to hemoglobin level. In keeping with other studies, 
patients with higher baseline hemoglobin were younger and more likely to be male.5,18 Comorbidities were 
more prevalent in patients with lower hemoglobin and this was particularly noticeable for diabetes; 
patients in the lowest quintile of hemoglobin were nearly twice as likely to be diabetic as compared to 
those in the highest quintile. Lower levels of lipids seen in patients with low hemoglobin (and thereby in 
those with worse prognosis) may well be a reflection of impaired general health. How all these 
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comorbidities inter-relate to affect both hemoglobin and long-term outcomes is complex. Whist the 
development of anemia might itself contribute to cardiovascular events, it is likely that at least part of its 
association with adverse prognosis is related to underlying comorbid disease given that it is also an 
independent predictor of noncardiovascular mortality. 
 A cause-effect relationship exists between renal function and hemoglobin – patients with reduced 
renal function are known to have lower hemoglobin. Some studies have suggested an additive risk of 
chronic kidney disease and anemia in patients undergoing percutaneous coronary intervention.5 In our 
study, low hemoglobin and anemia at follow-up were strong predictors of adverse outcome even after 
correcting for baseline renal function. Sensitivity analysis whereby patients with severe chronic kidney 
disease were excluded revealed qualitatively similar results.  
 Differences in treatments were seen across hemoglobin groups. From our data it is not possible 
to distinguish whether various treatments per se effects the development of anemia or whether 
hemoglobin influences prescribing practice. Despite a wide range of hemoglobin values very few patients 
did not receive either antiplatelet or oral anticoagulant therapy. Associated comorbidities are likely to play 
a role in differences; for example, the prescribing pattern of aspirin and anticoagulants could be in part be 
explained by associated atrial fibrillation. Higher use of thienopyridines was seen in stepwise fashion in 
lower hemoglobin quintiles despite lower rates of previous percutaneous coronary intervention. Overall 
use of nonsteroidal anti-inflammatory drugs was low in the total population, but was higher in patients with 
lower hemoglobin. A stepwise increase in prescription of proton pump inhibitors was seen with lower 
hemoglobin quintile. It is uncertain as to whether this relates to the presence of gastrointestinal disease or 
symptoms, or reflects a response to low hemoglobin or even contributes to anemia through the 
development of iron deficiency.24,25 
 Patients with lower hemoglobin more frequently received angiotensin receptor blockers and were 
less likely to be prescribed angiotensin-converting enzyme inhibitors. We have shown a similar pattern 
when patients with coronary artery disease are evaluated according to severity of renal dysfunction.11  
 This study has several limitations. The current study population comprises 66.3% of the total 
CLARIFY population, due to baseline hemoglobin being unavailable in the remainder (recent blood tests 
were not mandated for inclusion in the study). Owing in part to the large size of the study and the fact that 
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there appear to be regional differences in patients with and without blood test results, there are inevitably 
statistical differences between the two groups. This is another reason as to why we adjusted the analysis 
for geographic region. On inspection of the comparative data, the magnitude of difference and clinical 
relevance does not appear to be too large. Endpoints are all as reported by investigators without central 
adjudication. However, we do not expect major differences in ascertainment as a function of hemoglobin. 
At yearly follow-up visits, blood tests were included if available within the previous 12 months and exact 
dates for the blood results were not collected. The clinical indication for the blood test might add 
confounding. Anemia per se was not an exclusion criterion, but it is plausible that subjects with more 
severe reduction in hemoglobin may have been excluded based on this being considered as hampering 
the collection of 5-year follow-up data. As such, the results may not be applicable to patients with more 
severe anemia at baseline. Whilst we have adjusted for geographic region, data on presence of 
thallasemia trait in participants are lacking and could theoretically influence the results. 
 We did not collect data relating to the cause of anemia, such as hematinics (in particular ferritin 
was unavailable), or other indices of red blood cell status (including mean corpuscular volume or red cell 
distribution width) or markers of inflammation (e.g. C-reactive protein), which might be associated with 
adverse outcome in coronary artery disease.26 Knowledge of such data will be crucial to fully 
understanding the relationships we have demonstrated, and will be fundamental to planning prospective 
studies to see if correction of anemia is associated with improved outcomes in coronary artery disease. 
 
CONCLUSIONS 
Low hemoglobin is common and is an independent predictor of mortality, adverse cardiovascular events, 
and major bleeds in patients with stable coronary artery disease. Persisting or new onset anemia is a 
powerful predictor of cardiovascular and noncardiovascular mortality. More studies are required to 
establish the cause of low hemoglobin and whether correction, if possible, can translate into improved 
outcomes. In current clinical practice hemoglobin level should be considered an important marker in 
terms of assessment of prognosis and bleeding risk. Our data suggest that whilst low hemoglobin level 
may play a pathophysiological role in cardiovascular events, it is also likely to be a marker of coexisting 
disease. 
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Figure captions 
 
Figure 1 Flow chart showing the derivation of current study population. 
 
Figure 2 Four-year outcomes according to baseline hemoglobin status. (A) Unadjusted analysis with HRs 
for all-cause mortality, cardiovascular mortality, noncardiovascular mortality, major bleeding and 
composite of cardiovascular death, myocardial infarction or stroke according to quintile of baseline 
hemoglobin (reference: quintile 3). (B) Multivariable adjustment (reference: quintile 3) with HRs for 
patients grouped according to baseline quintile of hemoglobin. Adjusted for age, sex, geographic region, 
smoking status, dyslipidemia, myocardial infarction, percutaneous coronary intervention, coronary artery 
bypass graft, systolic blood pressure, diastolic blood pressure, left ventricular ejection fraction, heart 
failure, diabetes, peripheral artery disease, asthma/chronic obstructive pulmonary disease and baseline 
renal function. CI = confidence interval; CV = cardiovascular; HR = hazard ratio; MI = myocardial 
infarction. 
 
Figure 3 Four-year outcomes according to change in anemia status. (A) Unadjusted analysis with HRs 
for all-cause mortality, cardiovascular mortality, noncardiovascular mortality, major bleeding and 
composite of cardiovascular death, myocardial infarction or stroke according to anemia status (reference: 
N/N). (B) Multivariable adjustment (reference: N/N) with HRs for patients grouped according to anemia 
status. Adjusted for age, sex, geographic region, smoking status, dyslipidemia, myocardial infarction, 
percutaneous coronary intervention, coronary artery bypass graft, systolic blood pressure, diastolic blood 
pressure, left ventricular ejection fraction, heart failure, diabetes, peripheral artery disease, 
asthma/chronic obstructive pulmonary disease and baseline renal function. A/A = anemic at baseline and 
follow-up; A/N = anemic at baseline; normal at follow-up; CI = confidence interval; CV = cardiovascular; 
HR = hazard ratio; MI = myocardial infarction; N/A = normal at baseline; anemic at follow-up; N/N = 
normal at baseline and follow-up. 
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Table 1 Characteristics of study population classified according to baseline hemoglobin quintile  
 Hemoglobin quintile P Value* 
 Quintile 1 
(<12.80 g/dL)  
(n = 4186) 
Quintile 2 
(12.80-13.69 
g/dL) 
(n = 4333) 
Quintile 3 
(13.70-14.40 
g/dL) 
(n = 4610) 
Quintile 4 
(14.41-15.20 
g/dL)  
(n = 4353)  
Quintile 5 
(>15.20 g/dL) 
(n = 4347)  
Age − y 67.2 ± 10.5  65.3 ± 10.2  64.0 ± 10.3  62.6 ± 10.2  61.1 ± 10.2  <.001  
Male – n (%) 2312 (55.2)  2826 (65.2)  3721 (80.7)  3891 (89.4)  4138 (95.2)  <.001  
Geographic region – n (%)             
Western/Central Europe 1569 (37.5) 1895 (43.7) 2246 (48.7) 2042 (46.9) 2006 (46.1) <.001 
Eastern Europe 338 (8.1) 519 (12.0) 514 (11.1) 517 (11.9) 579 (13.3)   
Middle East 458 (10.9) 269 (6.2) 225 (4.9) 212 (4.9) 163 (3.7)   
East Asia 706 (16.9) 588 (13.6) 514 (11.1) 492 (11.3) 526 (12.1)   
India 260 (6.2) 115 (2.7) 87 (1.9) 46 (1.1) 19 (0.4)   
Central and South America 223 (5.3) 204 (4.7) 216 (4.7) 203 (4.7) 279 (6.4)   
Canada, South Africa, Australia 
and the UK 
632 (15.1) 743 (17.1) 808 (17.5) 841 (19.3) 775 (17.8)   
Body mass index − kg/m2 26.8 (24.2-30.2)  27.3 (24.7-30.5)  27.5 (25.0-30.4)  27.7 (25.3-30.7)  27.8 (25.6-30.9)  <.001  
Time since 1st coronary artery 
disease diagnosis − y 
4 (1-9)  4 (2-9)  5 (2-10)  5 (2-10)  5 (2-10)  <.001  
Myocardial infarction – n (%) 2428 (58.0)  2519 (58.1)  2793 (60.6)  2781 (63.9)  2860 (65.8)  <.001  
Percutaneous coronary 
intervention – n (%) 
2263 (54.1)  2424 (55.9)  2678 (58.1)  2530 (58.1)  2533 (58.3)  <.001  
CABG – n (%) 1143 (27.3)  1006 (23.2)  1102 (23.9)  1043 (24.0)  970 (22.3)  <.001  
Stroke – n (%) 233 (5.6)  194 (4.5)  148 (3.2)  152 (3.5)  171 (3.9)  <.001  
Transient ischemic attack – n (%) 169 (4.0)  167 (3.9)  127 (2.8)  146 (3.4)  115 (2.6)  <.001  
Peripheral artery disease – n (%) 498 (11.9)  464 (10.7)  465 (10.1)  430 (9.9)  407 (9.4)  .0017  
Hospitalization for chronic heart 
failure – n (%) 
374 (8.9)  245 (5.7)  193 (4.2)  173 (4.0)  163 (3.7)  <.001  
Treated hypertension – n (%) 3223 (77.0)  3183 (73.5)  3209 (69.6)  2993 (68.8)  2940 (67.6)  <.001  
Diabetes – n (%)†  1717 (41.0)  1312 (30.3)  1289 (28.0)  1152 (26.5)  994 (22.9)  <.001  
Dyslipidemia – n (%)†   3059 (73.1)  3265 (75.4)  3588 (77.8)  3326 (76.4)  3374 (77.6)  <.001  
Atrial fibrillation/flutter – n (%)  347 (8.3)  335 (7.7)  332 (7.2)  274 (6.3)  299 (6.9)  .005  
Asthma/chronic obstructive 
pulmonary disease – n (%) 
362 (8.6)  363 (8.4)  369 (8.0)  354 (8.1)  326 (7.5)  .37  
Smoking status – n (%)      <.001 
Current 301 (7.2)  463 (10.7)  543 (11.8)  601 (13.8)  835 (19.2)   
Former  1561 (37.3)  1822 (42.0)  2274 (49.3)  2299 (52.8)  2210 (50.8)   
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 Hemoglobin quintile P Value* 
 Quintile 1 
(<12.80 g/dL)  
(n = 4186) 
Quintile 2 
(12.80-13.69 
g/dL) 
(n = 4333) 
Quintile 3 
(13.70-14.40 
g/dL) 
(n = 4610) 
Quintile 4 
(14.41-15.20 
g/dL)  
(n = 4353)  
Quintile 5 
(>15.20 g/dL) 
(n = 4347)  
No chronic heart failure symptoms 
– n (%)† 
3396 (81.1)  3556 (82.1)  3893 (84.4)  3693 (84.8)  3618 (83.2)  <.001  
No physical activity – n (%)† 992 (23.7)  743 (17.1)  635 (13.8)  540 (12.4)  517 (11.9)  <.001  
Data are presented as mean ± SD, number (percentage), or median (Q1-Q3). 
CABG = coronary artery bypass graft; Q = quartile; SD = standard deviation.  
*For differences across quintiles.  
†Diabetes or dyslipidemia reflects a history of these conditions. Patients were asked regarding symptoms of heart failure – this was categorized 
according to either New York Heart Association class or absent. Physical activity was graded according to the amount undertaken per week. 
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Table 2 Clinical and physiologic findings according to hemoglobin quintiles. 
 Total  
no. with 
data 
available 
Hemoglobin quintile P 
value* 
 
Quintile 1 
(<12.80 g/dL)  
(n = 4186) 
Quintile 2 
(12.80-13.69 
g/dL)  
(n = 4333) 
Quintile 3 
(13.70-14.40 
g/dL)  
(n = 4610) 
Quintile 4 
(14.41-15.20 
g/dL)  
(n = 4353) 
Quintile 5 
(>15.20 g/dL)  
(n = 4347) 
Heart rate palpation − bpm 21,814 69.7 ± 11.1  68.0 ± 10.5  67.6 ± 10.7  67.3 ± 10.2  68.1 ± 10.6  <.001  
Systolic BP − mm Hg 21,817 132 ± 18  132 ± 17  131 ± 16  131 ± 16  131 ± 16  <.001  
Diastolic BP − mm Hg 21,817 76 ± 11  77 ± 10  77 ± 10  78 ± 10  79 ± 10  <.001  
LVEF − % 16,209  54.5 ± 12.0  56.3 ± 10.9  55.8 ± 10.6  56.3 ± 10.8  56.4 ± 10.8  <.001  
Fasting blood glucose − mmol/L 19,689  5.8 (5.1-7.0)  5.6 (5.0-6.6)  5.6 (5.1-6.6)  5.7 (5.1-6.6)  5.6 (5.1-6.4)  <.001  
Total cholesterol − mg/dL 20,681  162.1 (135.1-
193.0)  
166.0 (142.8-
193.0)  
166.0 (139.0-
193.0)  
166.0 (142.8-
193.0)  
166.0 (142.8-
196.9)  
<.001  
High-density lipoprotein − mg/dL 18,219  43.2 (36.3-53.3)  45.2 (38.2-54.0)  44.0 (37.4-53.3)  43.2 (37.1-52.1)  42.5 (36.7-50.2)  <.001  
Fasting triglycerides − mg/dL 19,072  115.1 (88.5-
168.2)  
123.9 (88.5-
168.2)  
123.9 (88.5-
168.2)  
123.9 (88.5-
177.0)  
132.8 (97.4-
177.0)  
<.001  
eGFR (CKD-EPI) − mL/min/1.73 
m2 
18,496 68.2 (51.7-85.6) 74.8 (60.9-88.7) 77.7 (64.2-90.4) 79.1 (66.7-91.6) 80.3 (67.7-92.2) <.001 
Data are presented as mean ± SD or median (Q1-Q3). 
BP = blood pressure; bpm = beats per minute; CKD-EPI = Chronic Kidney Disease-Epidemiology Collaboration; eGFR = estimated glomerular 
filtration rate; LVEF = left ventricular ejection fraction; Q = quartile; SD = standard deviation. 
*For differences across quintiles.  
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Table 3 Drug treatment for patients with available data according to baseline hemoglobin quintile  
Variable  No. Hemoglobin quintile P value* 
 Quintile 1 
(<12.80 g/dL)  
(n = 4186) 
Quintile 2 
(12.80-13.69 
g/dL)  
(n = 4333) 
Quintile 3 
(13.70-14.40 
g/dL)  
(n = 4610) 
Quintile 4 
(14.41-15.20 
g/dL)  
(n = 4353) 
Quintile 5 
(>15.20 g/dL)  
 
(n = 4347) 
Antiplatelet – n (%)        
Aspirin 21,827  3588 (85.7)  3825 (88.3)  4093 (88.8)  3870 (88.9)  3859 (88.8)  <.001 
Thienopyridine  21,827 1330 (31.8)  1220 (28.2)  1273 (27.6)  1134 (26.1)  1106 (25.5)  <.001  
Other antiplatelet  21,827 439 (10.5)  427 (9.9)  441 (9.6)  409 (9.4)  318 (7.3)  <.001  
Oral anticoagulant – n (%) 21,827 413 (9.9)  334 (7.7)  319 (6.9)  307 (7.1)  364 (8.4)  <.001  
Oral anticoagulant in atrial 
fibrillation† 
1,702 173 (45.8) 166 (46.5) 148 (41.9) 123 (41.8) 148 (46.3) .56 
Neither antiplatelet nor oral 
anticoagulant – n (%) 
21,829 78 (1.9) 73 (1.7) 63 (1.4) 59 (1.4) 77 (1.8) .19 
Beta-blocker – n (%)  21,828 3200 (76.4)  3278 (75.7)  3497 (75.9)  3281 (75.4)  3278 (75.4)  .78 
Ivabradine – n (%)  21,827 482 (11.5)  540 (12.5)  558 (12.1)  449 (10.3)  404 (9.3)  <.001  
Calcium antagonist – n (%)  21,826 1272 (30.4)  1275 (29.4)  1209 (26.2)  1116 (25.6)  1106 (25.5)  <.001  
Long-acting nitrate – n (%)  21,828 1209 (28.9)  1074 (24.8)  1002 (21.7)  862 (19.8)  817 (18.8)  <.001  
ACE inhibitor or ARB – n (%)  21,827  3277 (78.3)  3353 (77.4)  3596 (78.0)  3304 (75.9)  3235 (74.5)  <.001  
ACE inhibitor 21,827  1990 (47.5)  2169 (50.1)  2467 (53.5)  2384 (54.8)  2369 (54.5)  <.001  
ARB 21,825  1407 (33.6)  1284 (29.6)  1221 (26.5)  986 (22.7)  932 (21.4)  <.001  
Lipid-lowering drug – n (%) 21,829  3855 (92.1)  4060 (93.7)  4337 (94.1)  4079 (93.7)  4077 (93.8)  .002  
Statin  21,829 3453 (82.5) 3652 (84.3) 3905 (84.7) 3686 (84.7) 3728 (85.8) .001 
Diuretic – n (%) 21,828 1707 (40.8)  1407 (32.5)  1293 (28.0)  1101 (25.3)  1050 (24.2)  <.001  
Other antihypertensive drug – 
n (%) 
21,826 433 (10.3)  321 (7.4)  325 (7.0)  285 (6.5)  252 (5.8)  <.001  
NSAID – n (%) 21,824 241 (5.8)  225 (5.2)  230 (5.0)  198 (4.6)  163 (3.8)  <.001  
Proton pump inhibitor – n (%) 21,827 1337 (31.9)  1250 (28.8)  1303 (28.3)  1006 (23.1)  1004 (23.1)  <.001  
Antidiabetic drug – n (%) 21,828 1495 (35.7)  1118 (25.8)  1086 (23.6)  959 (22.0)  808 (18.6)  <.001  
ACE = angiotensin converting enzyme; ARB, angiotensin receptor blocker; NSAID, nonsteroidal anti-inflammatory drug.  
*For differences across quintiles.  
†Patients with history of (or currently in) atrial fibrillation.  
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CLINICAL SIGNIFICANCE 
• Patients with stable coronary artery disease and low hemoglobin are at increased risk of 
mortality, cardiovascular death/myocardial infarction/stroke, and major bleeding. 
• Normalizing anemic hemoglobin levels may decrease risk of mortality and cardiovascular events. 
• Hemoglobin levels in stable coronary artery disease should be tested and, if possible, corrected. 
• It is not known whether low hemoglobin has a role in cardiovascular events and/or is a marker of 
comorbidities. 
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Appendix 2. Four-year outcomes according to baseline hemoglobin status in men and in women 
Men 
Outcome     Level No. with event / No. in 
group 
HR (95% CI) Individual p-values Overall p-value 
All Cause Death - 
Univariate 
1: Quintile 1 349 / 3299 2.08 (1.74, 2.5) <0.0001  
2: Quintile 2 254 / 3769 1.27 (1.05, 1.55) 0.0147  
3: Quintile 3 170 / 3170 1.00 (-)  <0.0001 
4: Quintile 4 158 / 3295 0.89 (0.72, 1.11) 0.3021  
5: Quintile 5 162 / 3354 0.91 (0.73, 1.12) 0.3742  
All Cause Death - 
Adjusted for age, 
geographical region, 
smoking status, 
dyslipidemia, MI, PCI, 
CABG, SBP, DBP, 
LVEF, Diabetes, PAD, 
Asthma/COPD and 
baseline renal function 
1: Quintile 1 300 / 2822 1.35 (1.1, 1.66) 0.0040  
2: Quintile 2 223 / 3214 1.13 (0.91, 1.39) 0.2647  
3: Quintile 3 143 / 2627 1.00 (-)  0.0017 
4: Quintile 4 132 / 2763 0.91 (0.72, 1.16) 0.4535  
5: Quintile 5 144 / 2835 1.01 (0.8, 1.27) 0.9534  
Cardiovascular Death - 
Univariate 
1: Quintile 1 158 / 3299 1.92 (1.48, 2.51) <0.0001  
2: Quintile 2 103 / 3769 1.06 (0.79, 1.41) 0.7067  
3: Quintile 3 83 / 3170 1.00 (-)  <0.0001 
4: Quintile 4 75 / 3295 0.87 (0.63, 1.18) 0.3702  
5: Quintile 5 78 / 3354 0.89 (0.66, 1.22) 0.4745  
Cardiovascular Death - 
Adjusted for age, 
geographical region, 
smoking status, 
dyslipidemia, MI, PCI, 
CABG, SBP, DBP, 
LVEF, Diabetes, PAD, 
Asthma/COPD and 
baseline renal function 
1: Quintile 1 139 / 2822 1.39 (1.02, 1.89) 0.0347  
2: Quintile 2 87 / 3214 1 (0.72, 1.39) 0.9817  
3: Quintile 3 63 / 2627 1.00 (-)  0.0799 
 4: Quintile 4 64 / 2763 1.02 (0.72, 1.44) 0.9261  
 5: Quintile 5 69 / 2835 1.05 (0.75, 1.49) 0.7730 
 
 
 1: Quintile 1 123 / 3299 1.99 (1.47, 2.7) <0.0001  
 2: Quintile 2 109 / 3769 1.48 (1.08, 2.01) 0.0140  
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Non-Cardiovascular 
Death - Univariate 
3: Quintile 3 63 / 3170 1.00 (-)  <0.0001 
 4: Quintile 4 60 / 3295 0.91 (0.64, 1.3) 0.6214  
 5: Quintile 5 54 / 3354 0.82 (0.57, 1.17) 0.2745  
 1: Quintile 1 102 / 2822 1.11 (0.8, 1.55) 0.5257  
 2: Quintile 2 97 / 3214 1.16 (0.84, 1.6) 0.3767  
Non-Cardiovascular 
Death - Adjusted for 
age, geographical 
region, smoking status, 
dyslipidemia, MI, PCI, 
CABG, SBP, DBP, 
LVEF, Diabetes, PAD, 
Asthma/COPD and 
baseline renal function 
3: Quintile 3 60 / 2627 1.00 (-)  0.1105 
 4: Quintile 4 48 / 2763 0.79 (0.54, 1.16) 0.2250  
 5: Quintile 5 46 / 2835 0.8 (0.54, 1.18) 0.2642  
 1: Quintile 1 278 / 3296 1.34 (1.12, 1.6) 0.0015  
 2: Quintile 2 213 / 3769 0.86 (0.71, 1.04) 0.1151  
CV Death, MI or stroke 
- Univariate 
3: Quintile 3 210 / 3167 1.00 (-)  <0.0001 
 4: Quintile 4 169 / 3289 0.77 (0.63, 0.94) 0.0115  
 5: Quintile 5 203 / 3351 0.92 (0.76, 1.12) 0.3957  
 1: Quintile 1 245 / 2819 1.13 (0.93, 1.39) 0.2236  
 2: Quintile 2 186 / 3214 0.86 (0.7, 1.06) 0.1539  
CV Death, MI or stroke 
- Adjusted for age, 
geographical region, 
smoking status, 
dyslipidemia, MI, PCI, 
CABG, SBP, DBP, 
LVEF, Diabetes, PAD, 
Asthma/COPD and 
baseline renal function 
3: Quintile 3 169 / 2624 1.00 (-)  0.0161 
 4: Quintile 4 144 / 2758 0.82 (0.66, 1.02) 0.0804  
 5: Quintile 5 169 / 2833 0.94 (0.76, 1.17) 0.6016  
 1: Quintile 1 71 / 3167 2.92 (1.85, 4.6) <0.0001  
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 2: Quintile 2 53 / 3647 1.82 (1.13, 2.93) 0.0135  
Major Bleeding - 
Univariate 
3: Quintile 3 25 / 3094 1.00 (-)  <0.0001 
 4: Quintile 4 33 / 3196 1.27 (0.76, 2.14) 0.3644  
 5: Quintile 5 33 / 3257 1.26 (0.75, 2.12) 0.3804  
 1: Quintile 1 58 / 2710 2.22 (1.34, 3.66) 0.0019  
 2: Quintile 2 46 / 3112 1.63 (0.98, 2.72) 0.0598  
Major Bleeding - 
Adjusted for age, 
geographical region, 
smoking status, 
dyslipidemia, MI, PCI, 
CABG, SBP, DBP, 
LVEF, Diabetes, PAD, 
Asthma/COPD and 
baseline renal function 
3: Quintile 3 22 / 2574 1.00 (-)  0.0174 
 4: Quintile 4 29 / 2691 1.29 (0.74, 2.25) 0.3662  
 5: Quintile 5 28 / 2757 1.34 (0.76, 2.35) 0.3066  
 
 
Women 
Outcome Level No. with event / No. in group HR (95% CI) Individual p-values Overall p-value 
All Cause Death - 
Univariate 
1: Quintile 1 112 / 954 2.16 (1.57, 2.96) <0.0001  
2: Quintile 2 58 / 1080 0.93 (0.65, 1.33) 0.6821  
3: Quintile 3 59 / 1007 1.00 (-)  <0.0001 
4: Quintile 4 46 / 895 0.88 (0.6, 1.29) 0.5029  
5: Quintile 5 46 / 1003 0.79 (0.54, 1.16) 0.2271  
All Cause Death - 
Adjusted for age, 
geographical region, 
smoking status, 
dyslipidemia, MI, PCI, 
CABG, SBP, DBP, 
LVEF, Diabetes, PAD, 
Asthma/COPD and 
1: Quintile 1 98 / 840 1.33 (0.93, 1.91) 0.1156  
2: Quintile 2 52 / 901 0.82 (0.56, 1.21) 0.3182  
3: Quintile 3 52 / 843 1.00 (-)  0.0415 
4: Quintile 4 43 / 774 0.93 (0.62, 1.4) 0.7260  
5: Quintile 5 42 / 871 0.83 (0.55, 1.26) 0.3822  
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baseline renal function 
Cardiovascular Death - 
Univariate 
1: Quintile 1 49 / 954 1.73 (1.11, 2.7) 0.0162  
2: Quintile 2 27 / 1080 0.8 (0.48, 1.33) 0.3801  
3: Quintile 3 32 / 1007 1.00 (-)  <0.0001 
4: Quintile 4 14 / 895 0.49 (0.26, 0.92) 0.0269  
5: Quintile 5 24 / 1002 0.76 (0.45, 1.29) 0.3051  
Cardiovascular Death - 
Adjusted for age, 
geographical region, 
smoking status, 
dyslipidemia, MI, PCI, 
CABG, SBP, DBP, 
LVEF, Diabetes, PAD, 
Asthma/COPD and 
baseline renal function 
1: Quintile 1 44 / 840 1.04 (0.62, 1.75) 0.8756  
2: Quintile 2 25 / 901 0.71 (0.41, 1.24) 0.2291  
3: Quintile 3 27 / 843 1.00 (-)  0.2535 
4: Quintile 4 13 / 774 0.55 (0.28, 1.07) 0.0803  
5: Quintile 5 22 / 870 0.86 (0.49, 1.52) 0.6040  
Non-Cardiovascular 
Death - Univariate 
1: Quintile 1 46 / 954 2.77 (1.62, 4.73) 0.0002  
2: Quintile 2 21 / 1080 1.04 (0.56, 1.94) 0.8939  
3: Quintile 3 19 / 1007 1.00 (-)  <0.0001 
4: Quintile 4 18 / 895 1.06 (0.56, 2.03) 0.8498  
5: Quintile 5 14 / 1002 0.75 (0.37, 1.49) 0.4034  
Non-Cardiovascular 
Death - Adjusted for 
age, geographical 
region, smoking status, 
dyslipidemia, MI, PCI, 
CABG, SBP, DBP, 
LVEF, Diabetes, PAD, 
Asthma/COPD and 
baseline renal function 
1: Quintile 1 38 / 840 1.69 (0.93, 3.06) 0.0842  
2: Quintile 2 21 / 901 1 (0.53, 1.89) 0.9981  
3: Quintile 3 18 / 843 1.00 (-)  0.0879 
4: Quintile 4 16 / 774 0.99 (0.5, 1.95) 0.9754  
5: Quintile 5 12 / 870 0.69 (0.33, 1.45) 0.3318  
CV Death, MI or stroke 
- Univariate 
1: Quintile 1 78 / 952 1.62 (1.14, 2.28) 0.0065  
2: Quintile 2 65 / 1078 1.12 (0.78, 1.6) 0.5368  
3: Quintile 3 55 / 1005 1.00 (-)  0.0047 
4: Quintile 4 41 / 894 0.84 (0.56, 1.26) 0.4009  
5: Quintile 5 55 / 1001 1.01 (0.7, 1.47) 0.9470  
CV Death, MI or stroke 
- Adjusted for age, 
1: Quintile 1 69 / 838 1.21 (0.82, 1.77) 0.3432  
2: Quintile 2 58 / 899 1.04 (0.71, 1.53) 0.8301  
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geographical region, 
smoking status, 
dyslipidemia, MI, PCI, 
CABG, SBP, DBP, 
LVEF, Diabetes, PAD, 
Asthma/COPD and 
baseline renal function 
3: Quintile 3 48 / 841 1.00 (-)  0.7928 
4: Quintile 4 40 / 774 0.94 (0.61, 1.43) 0.7652  
5: Quintile 5 49 / 869 1.04 (0.7, 1.56) 0.8402  
Major Bleeding - 
Univariate 
1: Quintile 1 19 / 915 1.27 (0.66, 2.45) 0.4699  
2: Quintile 2 12 / 1049 0.67 (0.32, 1.39) 0.2795  
3: Quintile 3 17 / 982 1.00 (-)  0.1887 
4: Quintile 4 10 / 871 0.66 (0.3, 1.44) 0.2970  
5: Quintile 5 10 / 973 0.6 (0.27, 1.3) 0.1934  
Major Bleeding - 
Adjusted for age, 
geographical region, 
smoking status, 
dyslipidemia, MI, PCI, 
CABG, SBP, DBP, 
LVEF, Diabetes, PAD, 
Asthma/COPD and 
baseline renal function 
1: Quintile 1 17 / 809 1.12 (0.53, 2.35) 0.7669  
2: Quintile 2 10 / 874 0.65 (0.29, 1.47) 0.3009  
3: Quintile 3 14 / 823 1.00 (-)  0.4370 
4: Quintile 4 8 / 754 0.61 (0.26, 1.47) 0.2747  
5: Quintile 5 9 / 845 0.62 (0.27, 1.45) 0.2700  
 
CABG, coronary artery bypass graft; CI, confidence interval; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood pressure; HR, hazard ratio; 
LVEF, left ventricular ejection fraction; MI, myocardial infarction; PAD, peripheral artery disease; PCI, percutaneous coronary intervention; SBP, systolic blood 
pressure. 
  
 
